Endocrine Abstracts

Background: Conventional glucocorticoid (GC) replacement for congenital adrenal hyperplasia (CAH) induces unphysiological cortisol spikes. In contrast, modified-release hydrocortisone (MR-HC, Efmody) offers a more accurate imitation of the circadian cortisol release, particularly emphasizing the morning surge. The study compares quality of life and sleep-wake cycles in patients with CAH with conventional GC treatment and after a switch to MR-HC.Methods: ...

Background: Previous research has revealed variances in the composition of immune cells among patients with congenital adrenal hyperplasia (CAH) on conventional glucocorticoid (GC) replacement therapy compared to healthy controls. Modified-release hydrocortisone (MR-HC) optimizes cortisol pharmacokinetics, aligning with a more physiological circadian cortisol rhythm. This study therefore aims to assess the impact on the immune cell profile when transitioning patients with CAH ...